

The Power of NEXIUM— in an **Oral Suspension** Formulation

Dear Pharmaceutical Buyer:

AstraZeneca is pleased to announce the availability of a different formulation: **NEXIUM® (esomeprazole magnesium) For Delayed-Release Oral Suspension**. This is a powder that is mixed with water and can be administered orally, providing an option for patients who have difficulty swallowing capsules. **NEXIUM For Delayed-Release Oral Suspension** is available in both 20-mg and 40-mg doses.

Like NEXIUM Delayed-Release Capsules, **NEXIUM For Delayed-Release Oral Suspension** is indicated for the treatment of symptomatic GERD, the healing of EE, and the maintenance of healing of EE. The most frequently reported adverse events with NEXIUM include headache, diarrhea, and abdominal pain.

● **NEXIUM For Delayed-Release Oral Suspension is now available at your wholesaler. Call today to place your order!**

Please see the accompanying product specification sheet for **NEXIUM For Delayed-Release Oral Suspension** in 20-mg and 40-mg dosing strengths. Also, please see the Important Safety Information on the following page and accompanying full Prescribing Information for NEXIUM.

If you have any questions, please contact your wholesaler or your AstraZeneca National Account Director. Thank you for your support.

Sincerely,

James Liebman
Sales Director, Managed Care
Trade Sales, AstraZeneca




Nexium®
(esomeprazole magnesium)

Approved Uses

Healing of Erosive Esophagitis (EE)

For short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed EE.

Maintenance of Healing of EE

To maintain symptom resolution and healing of EE. Controlled studies do not extend beyond 6 months.

Symptomatic Gastroesophageal Reflux Disease (GERD)

For treatment of heartburn and other symptoms associated with GERD.

Important Safety Information

NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles.

The most frequently reported adverse events with NEXIUM include headache, diarrhea, and abdominal pain. Symptomatic response to therapy does not preclude the presence of gastric malignancy.

Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which NEXIUM is an enantiomer.

As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time.

Concomitant administration of esomeprazole may reduce the plasma levels of atazanavir.

NEXIUM should be used only for the conditions, dosages, and durations specified in the Prescribing Information. Please see accompanying full Prescribing Information.

NEXIUM is a registered trademark of the AstraZeneca group of companies.

© 2007 AstraZeneca LP. All rights reserved.

248308

Printed in U.S.A.

3/07



Nexium[®]
(esomeprazole magnesium)

AstraZeneca 